Transpochimeric Gene Transcript Biomarker Detection for Cancer Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer management methods are inefficient in approximately 75% of patients, and there is a need for personalized approaches that account for the molecular characteristics of tumors and patient genetic backgrounds to identify novel therapeutic targets and biomarkers for cancer staging, sensitivity prediction, and early detection of relapses.
Innovation Solution
A method involving the detection and classification of cancer subjects based on the presence or absence of specific nucleic acid sequences comprising transposable elements and gene sequences, such as POU5F1B, PLCB1, NXPE4, FAAH2, ME3, SNX1, PKP1, and MBD5, to predict prognosis and stage cancer, utilizing RNA-seq and bioinformatics for transcriptome analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer drugs are used, then treatment can be administered to patients, but treatment efficiency is low in close to 75% of patients
Solution Approach 1:
The patent applies local quality by identifying specific molecular characteristics (transposable element expression patterns) within the tumor's molecular makeup to guide treatment selection. Instead of uniform treatment approaches, the method characterizes local molecular features through RNA-seq analysis of TE expression profiles to match patients with personalized therapies, thereby improving treatment efficiency while maintaining adaptability to individual molecular characteristics
Solution Approach 2:
The patent utilizes parameter changes by measuring and analyzing the expression levels of transposable elements as molecular parameters. Through RNA-seq technology, the method quantifies TE expression patterns and uses these parameter variations to stratify patients into different risk groups and predict treatment response, enabling data-driven personalization of cancer therapy
2Loss of information
If comprehensive characterization of TE expression patterns is pursued, then novel biomarkers can be discovered, but lack of proper technologies prevents complete characterization
Solution Approach 1:
The patent applies universality by using RNA-seq technology, a multi-functional platform that simultaneously performs genome-wide transcriptional profiling, identifies transposable element expression patterns, discovers novel biomarkers, and enables clinical sample analysis. This single technology platform accomplishes multiple objectives that previously required separate specialized methods, thereby achieving comprehensive TE characterization without proportionally increasing device complexity
Solution Approach 2:
The patent introduces bioinformatics pipelines as an intermediary between raw RNA-seq data and biological insights. These computational tools mediate the analysis by assembling transcripts, identifying TE-gene chimeric transcripts, and characterizing expression patterns, thereby bridging the gap between technology output and biological understanding without requiring direct complex experimental interventions
3Measurement precision
If RNA-seq and bioinformatics pipelines are used, then TE-derived transcriptome can be deciphered, but advanced technology and computational resources are required
Solution Approach 1:
The patent applies segmentation by dividing the complex transcriptome analysis into distinct computational modules: initial RNA-seq data processing, transcript assembly, TE-gene chimeric transcript identification, and expression pattern characterization. This segmented approach allows each module to be optimized independently and facilitates the use of standardized bioinformatics tools, reducing overall computational complexity while maintaining high measurement precision through specialized analysis at each stage
4Adaptability or versatility
If personalized cancer management is implemented, then treatment selection based on molecular characteristics improves, but novel methods are needed to discover therapeutic targets and biomarkers
Solution Approach 1:
The patent applies preliminary action by performing comprehensive TE expression profiling and biomarker discovery in advance, before clinical treatment decisions are made. Through prospective RNA-seq analysis of tumor samples, the method pre-identifies patients with specific TE expression patterns associated with poor prognosis or treatment resistance, allowing clinicians to select personalized therapies based on pre-established molecular criteria rather than trial-and-error approaches
Data Source
AI summary
The invention relates to methods for detecting or predicting the likelihood of a cancer in a subject as well as to compositions, pharmaceutical compositions and methods of treatment of cancer.